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Patients: 221 people 18 years or over with bipolar disorder (DSM-IV) hospitalised for an acute manic or mixed episode. Exclusions: serious neurological abnormalities; seizure disorders; drug or AIDS induced mania; uncontrolled medical comorbidity; taking anticoagulants; breastfeeding or likely to become pregnant.
Intervention: Divalproex sodium (15-20 mg/kg/day) or lithium (up to 1800 mg/day in the acute treatment phase; 900-1200 mg/day in the maintenance phase). All participants also received usual psychiatric care.
Outcomes: Quality of life (QOL; SF-36 mental and physical component summaries, Mental Health Index-17); months without DSM-IV mania and depression estimated direct medical costs (estimates in 1997 US$).
Patient follow up: 77.8% at 12 months.
MAIN RESULTS
There were no significant differences at 12 months between divalproex and lithium in quality of life or time spent with mania and depression (see http://www.ebmentalhealth.com/supplemental for table). Most participants discontinued their medication during follow up (61% with divalproex and 60% with lithium). Overall medical costs were similar in the two groups (mean annual cost: US$28,911 divalproex v US$30,666 lithium, p = 0.693).
CONCLUSIONS
Clinical outcome, quality of life, and medical costs were similar with lithium and divalproex in people with bipolar disorder.
NOTES
In addition to their allocated treatment, participants could be prescribed other drugs as needed. During the first three months of the study, 14% of the divalproex group also received lithium and 18% of the lithium group also received divalproex, which may bias towards finding no difference between treatments. Analyses were not by intention to treat, because people who did not provide any follow data were excluded. 
Commentary
T his pragmatic study comparing divalproex and lithium in the treatment of bipolar disorder reveals important and clinically relevant information pertaining to effectiveness and associated costs of treatment that are far too often neglected in both our scientific literature and our day to day practice of medicine.
Revicki et al studied 221 people randomly assigned to treatment with either divalproex or lithium for hospitalised manic or mixed episodes and followed out for one year. Their finding of no significant difference between groups in terms of length of hospital stay (about 11 days in each group) is similar to previous findings.
1 No significant differences were found between people treated with divalproex and lithium in terms of clinical symptom efficacy, quality of life, and disability days. New findings pertaining to the practical effectiveness of these two treatments as it relates to medical costs bear considerable import. Although the mean estimated total medical costs for the two treatment groups were comparable ($28,911 for divalproex v $30,666 for lithium), as a whole, patients continuing mood stabiliser therapy at three months had better health outcomes and much lower medical costs associated with their care than those who discontinued therapy. The dropout rate for discontinuation due to adverse effects of medication was 7% in divalproex treated participants and 14% in lithium treated participants.
This study poses issues that are in some ways parallel to those raised by the CATIE study for schizophrenia.
2 Those who discontinue their medication early in the course of treatment, which happens more frequently than not it would appear, have worse outcomes and greater costs associated with their medical treatment-regardless of which drug(s) are chosen. Revicki et al rightly point out implications for clinical practice based on their observation that early treatment dropouts were more likely to have a history of suicidal behaviour and were more likely discharged into an unsupervised residential setting-that post discharge planning is essential for optimising recovery of health and functioning. Clinicians should strive to improve the continuity of care for inpatients into the outpatient setting and the continuation of care once thus established, in the hope of improving adherence and effectiveness which directly affect costs of care.
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